NCT05002569: An ongoing trial by Bristol-Myers Squibb
This trial is ongoing. It must report results 3 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05002569 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 19, 2021 |
| Completion date | Dec. 16, 2024 |
| Required reporting date | Dec. 16, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 12, 2025 |
| Days late | None |